Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Stage I Multiple Myeloma”

812 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 812 results

Testing effectiveness (Phase 2)Study completedNCT00024466
What this trial is testing

Chemotherapy, Vaccine Therapy, and Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 28
Early research (Phase 1)Not Yet RecruitingNCT07660939
What this trial is testing

GPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders

Who this might be right for
Plasma Cell DisordersMultiple Myeloma (MM)
Peking University First Hospital 50
Testing effectiveness (Phase 2)Study completedNCT07102706
What this trial is testing

Phase I Trial of GR1803 Injection in Patients With RRMM

Who this might be right for
Multiple Myeloma (MM)
Genrix (Shanghai) Biopharmaceutical Co., Ltd. 76
Testing effectiveness (Phase 2)WithdrawnNCT00004040
What this trial is testing

Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy

Who this might be right for
LeukemiaMultiple Myeloma and Plasma Cell Neoplasm
Hoag Memorial Hospital Presbyterian
Early research (Phase 1)Study completedNCT00060645
What this trial is testing

Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)

Who this might be right for
TumorsLymphomaMultiple Myeloma
Merck Sharp & Dohme LLC 33
Testing effectiveness (Phase 2)Study completedNCT00003572
What this trial is testing

Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers

Who this might be right for
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+1 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 20
Testing effectiveness (Phase 2)Study completedNCT01668719
What this trial is testing

S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma

Who this might be right for
DS Stage I Plasma Cell MyelomaDS Stage II Plasma Cell MyelomaDS Stage III Plasma Cell Myeloma
SWOG Cancer Research Network 142
Not applicableStudy completedNCT00408681
What this trial is testing

Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia in Remission+111 more
Fred Hutchinson Cancer Center 20
Testing effectiveness (Phase 2)Study completedNCT00003887
What this trial is testing

Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation

Who this might be right for
Breast CancerChronic Myeloproliferative DisordersGestational Trophoblastic Tumor+9 more
Fred Hutchinson Cancer Center
Testing effectiveness (Phase 2)Ended earlyNCT00985907
What this trial is testing

Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple MyelomaPatient Participation
University of California, San Francisco 13
Early research (Phase 1)UnknownNCT05005299
What this trial is testing

Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation

Who this might be right for
Leukemia, Myeloid, AcuteLeukemia, Lymphoblastic, Acute, L1Leukemia, Lymphoblastic, Acute, L2+3 more
Melbourne Health 18
Early research (Phase 1)Study completedNCT04811898
What this trial is testing

A Dose Escalation Study of LNA-i-Mir-221 for Cancer Treatment

Who this might be right for
Multiple Myeloma, RefractoryHepatocarcinomaAdvanced Solid Tumor
Azienda Ospedaliera Universitaria Mater Domini, Catanzaro 17
Testing effectiveness (Phase 2)Study completedNCT00708292
What this trial is testing

A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Novartis Pharmaceuticals 29
Early research (Phase 1)Looking for participantsNCT03909412
What this trial is testing

Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma

Who this might be right for
Multiple Myeloma
Hackensack Meridian Health 18
Testing effectiveness (Phase 2)Study completedNCT00506857
What this trial is testing

Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support

Who this might be right for
Hematologic Malignancies
M.D. Anderson Cancer Center 82
Early research (Phase 1)Study completedNCT03111992
What this trial is testing

Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Novartis Pharmaceuticals 26
Testing effectiveness (Phase 2)Study completedNCT00448357
What this trial is testing

Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+2 more
UNC Lineberger Comprehensive Cancer Center 54
Testing effectiveness (Phase 2)Study completedNCT00084747
What this trial is testing

Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Jonsson Comprehensive Cancer Center 30
Early research (Phase 1)WithdrawnNCT02786485
What this trial is testing

Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT

Who this might be right for
LeukemiaMyelodysplastic SyndromesLymphomas+2 more
Bellicum Pharmaceuticals
Not applicableEnded earlyNCT00897910
What this trial is testing

Studying T Cells in Blood and Bone Marrow Samples From Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Barbara Ann Karmanos Cancer Institute 6
Next Page